Trusted Resource for Clinical Trials, Protocols & Progress
As per CDSCO, ICH GCP, and EMA guidance, investigators must tailor the consent process to accommodate cultural and linguistic needs of vulnerable populations. Ethics Committees may mandate additional documentation or procedures in such contexts.
Click to read the full article.
Use eConsent platforms that offer:
Click to read the full article.
Modern eConsent tools can manage multilingual content, version control, electronic signatures, and audit trails across regions. Ensure your platform complies with 21 CFR Part 11, GDPR, and local data protection laws.
Click to read the full article.
Re-consent is the process of obtaining renewed informed consent from a participant after their initial consent, due to changes that may affect their decision to continue. This includes new safety information, protocol amendments, changes in study design, or eligibility criteria updates.
Click to read the full article.
In a pediatric epilepsy trial, 22 participants turned 18 during the 2-year follow-up. The sponsor had pre-approved adult ICFs ready, and site coordinators obtained re-consent during the next study visit. All forms were tracked in the TMF and verified during the GMP audit process, with zero findings related to re-consent.
Click to read the full article.
eConsent refers to the use of electronic systems and processes that support obtaining, documenting, and managing informed consent. It includes multimedia content, digital signatures, and secure cloud storage. For re-consent, these platforms enable seamless re-engagement of participants when significant protocol changes occur or when long-term extension studies are initiated.
Click to read the full article.
LTE studies are follow-up clinical trials offered to participants who completed a parent study. Objectives may include:
Click to read the full article.
Regulators expect sites to show not just consent, but also the process by which comprehension was assured. For instance, Stability Studies emphasize real-world reproducibility, which parallels the need for verifiable participant understanding in clinical settings.
Click to read the full article.
Re-consent is triggered when there are substantial changes in the study protocol or newly discovered safety data that could affect the participant’s willingness to continue.
Click to read the full article.
Many sites are transitioning to electronic consent (eConsent) systems, which facilitate version tracking, time stamping, and remote audit readiness. Ensure your system meets FDA 21 CFR Part 11 or EMA Annex 11 compliance requirements.
Click to read the full article.
